VKVineet Kumar Kamal

Vineet Kumar Kamal

*This is an algorithmically generated author record based on publicly available information.

Vineet Kumar Kamal has a total of 183 co-authors. Here are the top co-authors by number of shared publications:

  • Abhishek Shankar

    Department of Radiation Oncology, Dr BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Delhi, India

    7 shared publications
  • Shubham Roy

    Abhishek Shankar and Goura Kishor Rath, Dr BR Ambedkar Institute Rotary Cancer Hospital; Abhishek Shankar, Goura Kishor Rath, and Vineet Kumar Kamal, All India Institute of Medical Sciences; Shubham Roy, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi; Abhijit Chakraborty, Netaji Subhas Chandra Bose Cancer Research Institute; and Aalekhya Sharma Biswas, Maulana Abul Kalam Azad University of Technology, Kolkata, India

    6 shared publications
  • Sameer Bakhshi

    Department of Medical Oncology, Dr BRA IRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, India

    5 shared publications
  • Deepak Agrawal

    Department of Neuro Surgery, All India Institute of Medical Sciences (AIIMS), New Delhi, India

    4 shared publications
  • Renu Saxena

    Department of Hematology, All India Institute of Medical Sciences, New Delhi 110029, India

    4 shared publications
  • Abhidha Malik

    Department of Radiation Oncology, Dr. B.R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Delhi, India

    3 shared publications

Latest Publications

  • Open Access

    Development, validation and clinical utility of prognostic models for patients with traumatic brain injury in an Indian setting using machine learning and traditional approaches: a study protocol

    by Vineet Kumar Kamal, Deepak Agrawal, Anil Kumar, Raghavendran Radhakrishnan, Manickam Ponnaiah, Deepana Ramaiya, Arumugam Thiruvalluvan, Aditya Sivaram

    Introduction Traumatic brain injury (TBI) remains a major public health concern in India, with high mortality and long-term disability. Existing prognostic models, mostly developed in high-income countries using traditional methods, lack generalisability to the Indian context and do not use the potential of machine learning or multicentric data. This study primarily aims to develop, compare and validate machine learning methods, including the traditional approach, to predict 30-day mortality and 6-month functional outcomes in patients with moderate or severe TBI. A secondary objective is to describe and compare admission characteristics and outcomes (at discharge, 3 months, 6 months and 1 year) in TBI patients in tertiary care settings using descriptive analyses. Methods and analysis Data from the neurotrauma registry at Jai Prakash Narayan Apex Trauma Centre, department of neurosurgery, All India Institute of Medical Sciences (AIIMS), New Delhi, including patients admitted between 23 March 2022 and 22 September 2024, will be used for model development and internal validation. For external validation, retrospectively collected data from the same centre (May 2010 to August 2013) and prospectively collected data from AIIMS Patna (1 June 2022 to 30 November 2024) and Rajiv Gandhi Government General Hospital, Madras Medical College (MMC), Chennai (1 May 2022 to 31 October 2024) will be included. Prediction models for 30-day mortality and 6-month functional outcomes will be developed using both machine learning and traditional statistical techniques. Model performance will be evaluated based on discrimination, calibration and clinical utility, with the latter assessed through decision curve analysis (DCA). An online risk calculator will be developed based on the best-performing model to estimate outcome probabilities along with 95% CIs. Ethics and dissemination The institutional Ethics Review Board of respective data collection centres, that is, AIIMS, New Delhi, AIIMS, Patna, and MMC, Chennai, approved the study. Findings will be published in peer-reviewed journals and disseminated at national and international conferences. Discussion This study will develop and validate prognostic models using traditional and machine learning methods tailored to the Indian TBI context. Multicentric, prospectively collected data will enhance generalisability, while clinical utility will be evaluated through DCA. Adherence to Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis + Artificial Intelligence (TRIPOD+AI) guidelines ensures methodological transparency. With external validation, these models may improve clinical decision-making, resource planning and patient-family communication in diverse Indian healthcare settings.


  • Open Access

    Molecular characterization of Hepatitis C Virus (HCV) from hospitalised cases of hepatitis in six northeastern states of India

    by H. Kaur, B. J. Saikia, S. Medhi, A. K. Das, T. Majumdar, K. G. Lynrah, Lalrothuama, D. Biswas, T. Temsu, N. Sarmah, et al.

    Background: Viral hepatitis is of global importance and inflicts a huge healthcare cost in northeast India where its prevalence and the prevalence of drug-resistant variants are not well known. Hepatotropic viruses (hepatitis B virus, hepatitis A virus, hepatitis C virus and hepatitis E virus) are known to cause ‘viral hepatitis.’ This study documents the prevalence and genotype of Hepatitis C Virus (HCV) in northeast India.Aim: Identification of Hepatitis C Virus (HCV) genotypes with their resistance-associated variants (RAVs) could facilitate the development of selective antiviral drug regimens against HCV infection. The present study aims to identify the HCV genotype from six northeastern states of India.Methods: The study was carried out between 2018-2022 from hospitalised cases of viral hepatitis in six northeastern states of India namely Assam, Meghalaya, Mizoram, Nagaland, Tripura and Manipur. A total of 1300 subjects were enrolled, from whom 88 HCV-positive samples were processed for molecular characterisation.Results: Of the 88 samples evaluated for genotyping and sub-typing, 58 (66%) were HCV genotype 3b, 15 (17%) were 3a, 8 (9 %) were 6n, 2 (2%) were 6xa, 3 (3 %) were 1a, and 2 (2 %) were 1b respectively. Genotype 6n was common among injecting drug users (IDUs) (5/8; 62.5%). Resistance-associated variants (RAVs) 30K and 31M of HCV NS5A region were observed in 5/30 (16.6%) HCV genotype 3b. This could indicate likely resistance to directly acting antivirals (DAAs) targeting the NS5A of HCV. RAVs C316N mutation of NS5B region was also observed in 1/1 (100%) of HCV genotypes 1b.Conclusion: A higher prevalence of HCV genotype 3b was observed in the study population. Furthermore, overlapping of RAVs 30K and 31M of HCV NS5A region with HCV genotype 3b may pose treatment failure. Genotypes HCV 6n and HCV 6xa were also identified, which may be the first to be reported from northeastern parts of India.

  • Open Access

    Assessment of Bone Thickness at the Infra Zygomatic Crest Region for Various Orthodontic Miniscrew Implant (OMSI) Insertion Angles: A Cone-Beam Computed Tomographic Study

    by Jitendra Sharan, Atul Bajoria, Ashok Kumar Jena, Pallawi Sinha, Arunachalam Shivakumar, Vineet Kumar Kamal, Anand Marya

    To evaluate the infrazygomatic crest (IZC) bone and develop guidelines for the optimum placement of orthodontic miniscrew implants (OMSIs) along the distobuccal root of the permanent maxillary first molar. Bone thickness of the IZC region of 50 young adults (25 males and 25 females) aged 18-30 years were evaluated using cone-beam computed tomography images. The infrazygomatic bone thickness along the distobuccal root of the permanent maxillary first molar was assessed at various insertion angles (40° to 75° i.r.t the maxillary occlusal plane) with an increment of 5°. Student's t-test was used to compare the IZC bone thickness and height at the orthodontic miniscrew insertion site for males and females on the right and left sides. The bone thickness of the IZC region above the distobuccal root of the permanent maxillary first molar was estimated between 4.39±0.25 mm and 9.03±0.45 mm for insertion angles from 40° to 75° to the maxillary occlusal plane. The corresponding OMSI insertion heights were 17.71±0.61 mm to 13.69±0.75 mm, respectively, above the maxillary occlusal plane. There were statistically significant gender and side-wise variations in bone thickness at the IZC area and insertion height. The safe position for OMSI placement at the IZC was 13.69-16 mm from the maxillary occlusal plane with an insertion angle between 55° and 75°. These parameters provide the optimum placement of OMSIs along the distobuccal root of the permanent maxillary first molar.


  • Open Access

    Does the use of platelet-rich fibrin enhance the rate of orthodontic tooth movement? A systematic review and meta-analysis

    by Jitendra Sharan, Indumathi Shivakumar, Arunachalam Shivakumar, Vineet Kumar Kamal, Prabhat Kumar Chaudhari, Srikrishna Challasany, Anand Marya


  • Open Access

    Prevalence and risk factors associated with undiagnosed diabetes in India: Insights from NFHS-5 national survey

    by Pravin Sahadevan, Vineet Kumar Kamal, Akhil Sasidharan, Bhavani Shankara Bagepally, Dolly Kumari, Anita Pal

    Diabetes is a chronic metabolic disorder characterised by persistent hyperglycaemia, which can lead to complications including cardiovascular disease, kidney failure and blindness [1]. It is one of the fastest-growing health emergencies globally and a major public health concern in India, where the number of individuals with diabetes is expected to increase from 74.2 million in […]


  • Open Access

    Prevalence and risk factors associated with undiagnosed hypertension among adults aged 15 – 49 in India: insights from NFHS-5 national survey

    by Pravin Sahadevan, Akhil Sasidharan, Bhavani Shankara Bagepally, Anita Pal, Dolly Kumari, Prabhdeep Kaur, Manoj Murhekar, Vineet Kumar Kamal

    Undiagnosed Hypertension, especially among adults, is a significant public health concern, considering its long-term complications. We have estimated the prevalence and factors associated with undiagnosed hypertension in India. We used data from the fifth round of the National Family Health Survey (NFHS-5, 2019-21) to estimate the prevalence of undiagnosed hypertension among individuals aged between 15 to49) years. A log-binomial model with survey-adjusted Poisson regression was used to estimate the prevalence ratio between undiagnosed and diagnosed hypertension. Multinomial logistic regression analysis examined the factors associated with diagnosed hypertension (vs healthy) and undiagnosed hypertension (vs healthy). All the analyses were survey-weight adjusted and stratified by gender. Results are reported with 95% confidence intervals. The survey-adjusted prevalence of undiagnosed hypertension was 8.75% (8.62% to 8.87%) and was higher among males [13.56% (13.03% to 14.12%)] than in females [8.14% (8.03% to 8.25%)]. The proportion of individuals with undiagnosed hypertension among total hypertension was 44.99% (44.44% to 45.55%) and is higher in males [65.94% (64.25% to 67.60%)] than in females [42.18% (41.66% to 42.71%)]. Increasing age, higher body mass index, access to health care, and having comorbidities were risk factors for undiagnosed for hypertension. One in twelve people had undiagnosed hypertension, and of those with hypertension, one in two were undiagnosed, with males being disproportionately affected. Targeted public health interventions are crucial to improve hypertension screening, particularly among middle-aged and obese individuals without comorbidities. The findings also reveal disparities in hypertension burden among population subgroups in India, underscoring the need for targeted efforts.

  • Proposal and clinical application of molecular genetic risk scoring system, “MRplus”, for BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia- report from a single centre

    by Sanjeev Kumar Gupta, Sameer Bakhshi, Vineet Kumar Kamal, Ritu Gupta, Preity Sharma, Deepam Pushpam, Ranjit Kumar Sahoo, Atul Sharma


  • Open Access

    Development and temporal external validation of a simple risk score tool for prediction of outcomes after severe head injury based on admission characteristics from level-1 trauma centre of India using retrospectively collected data

    by Vineet Kumar Kamal, Ravindra Mohan Pandey, Deepak Agrawal

    Objective To develop and validate a simple risk scores chart to estimate the probability of poor outcomes in patients with severe head injury (HI). Design Retrospective. Setting Level-1, government-funded trauma centre, India. Participants Patients with severe HI admitted to the neurosurgery intensive care unit during 19 May 2010–31 December 2011 (n=946) for the model development and further, data from same centre with same inclusion criteria from 1 January 2012 to 31 July 2012 (n=284) for the external validation of the model. Outcome(s) In-hospital mortality and unfavourable outcome at 6 months. Results A total of 39.5% and 70.7% had in-hospital mortality and unfavourable outcome, respectively, in the development data set. The multivariable logistic regression analysis of routinely collected admission characteristics revealed that for in-hospital mortality, age (51–60, >60 years), motor score (1, 2, 4), pupillary reactivity (none), presence of hypotension, basal cistern effaced, traumatic subarachnoid haemorrhage/intraventricular haematoma and for unfavourable outcome, age (41–50, 51–60, >60 years), motor score (1–4), pupillary reactivity (none, one), unequal limb movement, presence of hypotension were the independent predictors as its 95% confidence interval (CI) of odds ratio (OR)_did not contain one. The discriminative ability (area under the receiver operating characteristic curve (95% CI)) of the score chart for in-hospital mortality and 6 months outcome was excellent in the development data set (0.890 (0.867 to 912) and 0.894 (0.869 to 0.918), respectively), internal validation data set using bootstrap resampling method (0.889 (0.867 to 909) and 0.893 (0.867 to 0.915), respectively) and external validation data set (0.871 (0.825 to 916) and 0.887 (0.842 to 0.932), respectively). Calibration showed good agreement between observed outcome rates and predicted risks in development and external validation data set (p>0.05). Conclusion For clinical decision making, we can use of these score charts in predicting outcomes in new patients with severe HI in India and similar settings.